R&D Spending Showdown: Axsome Therapeutics, Inc. vs Dynavax Technologies Corporation

Biotech R&D: Axsome's Surge vs. Dynavax's Shift

__timestampAxsome Therapeutics, Inc.Dynavax Technologies Corporation
Wednesday, January 1, 2014427920084580000
Thursday, January 1, 2015677698786943000
Friday, January 1, 20162119986084493000
Sunday, January 1, 20171995761664988000
Monday, January 1, 20182349505574951000
Tuesday, January 1, 20195364706762331000
Wednesday, January 1, 20207024457928607000
Friday, January 1, 20215806072532228000
Saturday, January 1, 20225794744746600000
Sunday, January 1, 20239794400054886000
Monday, January 1, 2024187077000
Loading chart...

Unleashing insights

R&D Spending Trends: A Decade of Innovation

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Axsome Therapeutics, Inc. and Dynavax Technologies Corporation have demonstrated contrasting R&D investment strategies.

From 2014 to 2023, Axsome Therapeutics increased its R&D expenses by over 2,000%, peaking in 2023 with a remarkable 98 million dollars. This surge underscores Axsome's aggressive pursuit of new therapeutic solutions. In contrast, Dynavax Technologies, while maintaining a robust R&D budget, saw a 35% decrease from its 2014 peak of 85 million dollars to 55 million dollars in 2023. This shift may reflect a strategic pivot or a focus on optimizing existing products.

These trends highlight the dynamic nature of biotech investments, where strategic R&D spending can significantly influence a company's trajectory and market position.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025